natgillin/translations-raw huggingface dataset:
The compound according to claim 1, wherein the compound is vortioxetine (DL)-pyroglutamate a-form in crystalline form with XRPD reflections at 14.27, 15.75, 17.06 and 18.59 (°2θ) (±0.1 °2θ). 
Spoj prema patentnom zahtjevu 1, naznačen time što je a-oblik vortioksetin (DL)-piroglutamata u kristalnom obliku s XRPD refleksijama kod 14,27, 15,75, 17,06 i 18,59 (220) (+0,1 220).
The following parameters were measured. 
Izmjereni su slijedeći parametri.
fractionated coconut oil and arachis oil). 
frakcionirano kokosovo ili kikirikijevo ulje).
The packaged composition of claim 17, characterized in that the packaging material is a tube. 
Pakirani pripravak iz patentnog zahtjeva 20, naznačen time, da je materijal za pakiranje tuba.
The method of claim 16, wherein the target DNA is inside of a cell and the method comprises introducing into the cell the single molecule DNA-targeting RNA or a nucleic acid that encodes the single molecule DNA-targeting RNA. 
RNK jednostruke molekule koja cilja na DNK, ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira navedenu RNK jednostruke molekule koja cilja na DNK, pri čemu RNK jednostruke molekule koja cilja na DNK, obuhvaća sljedeće:
Some such polypeptides comprise a polypeptide sequence which differs from the selected polypeptide sequence in no more than 10, 9, 8, 7, or 6 amino acid residues (e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues) and which includes amino acid residues at one or more of amino acid residue positions 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 and 106 that are identical to the amino acid residues at the corresponding positions in the selected polypeptide sequence. 
PATENTNI ZAHTJEVI Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka 1 koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 1 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
said heavy chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.5, a CDR2 having a sequence as set forth in SEQ ID NO.6, and a CDR3 having a sequence as set forth in in SEQ ID NO.7; and said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.10, a CDR2 having a sequence as set forth in SEQ ID NO.11, and a CDR3 having a sequence as set forth in SEQ ID NO.12; 
navedena varijabilna regija teškog lanca sadrži CDR1 koji ima sekvencu kako je navedeno u SEQ ID NO.5, CDR2 ima sekvencu kako je navedeno u SEQ ID NO.6, i CDR3 ima sekvencu kako je navedeno u SEQ ID NO .7; i navedena varijabilna regija lakog lanca sadrži CDR1 koji ima sekvencu kako je navedeno u SEQ ID NO.10, CDR2 ima sekvencu kako je navedeno u SEQ ID NO.11, i CDR3 ima sekvencu kako je navedeno u SEQ ID NO. 12;
It is further appreciated that when the GPR119 agonist and the DPP-IV inhibitor are in separate dosage forms, GPR119 agonist and DPP-IV inhibitor can be administered by different routes. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119, te DPP-IV inhibitor je inhibitor humanog DPP-IV.
A composition comprising an antibody or an antigen binding fragment thereof specific for at least one epitope of hsp90 from an organism of the Aspergillus genus, and at least one antifungal agent selected from the group consisting of: itraconazole and voriconazole. 
PATENTNI ZAHTJEVI ll. Kompozicija naznačena time što sadrži antitijelo ili njegov dio koji se veže za antigene koji su specifični za najmanje jedan epitop hsp90 iz organizma roda Aspergillus, i najmanje jedno anti-gljivično sredstvo koje je izabrano iz grupe koju čine: itrakonazol i vorikonazol.
The mobile station device (50) according to claim 4, wherein the mobile station device (50) is further adapted to manage the uplink synchronous status by using the timer wherein the uplink synchronous status is sustained until the timer expires. A method executed by a mobile station device (50) comprising: 
Postupak obrade prema zahtjevu 5, naznačen time da je uređaj mobilne stanice (50) nadalje prilagođen da upravlja sinkronim statusom uzlazne veze korištenjem vremenskog brojača tako da se sinkroni status uzlazne veze održava sve dok istekne vremenski brojač nakon što se vremenski brojač resetira, te pri čemu korak odbacivanja sadrži, u sinkronom statusu uzlazne veze, ne resetiranje vremenskog brojača na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
The combination for the use according to claim 1 or 2, wherein R1 represents a heterocyclic group which may be substituted; R2 represents a carboxyl group; and R3 represents a hydroxyl group. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da R' predstavlja heterocikličku skupinu koja može biti supstituirana;
wherein the aluminum powder comprises a particle size distribution characterized in that a 50th percentile of a particle size distribution has a diameter of between about 4 to 7 microns and a 90th percentile of a particle size distribution has a diameter of less than or equal to about 11.5-15.5 microns. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 4 i 7 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 11.5-15.5 mikrometara.
is NR10R11 or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; 
predstavlja piperidinski ili pirolidinski prsten, kojeg opcionalno supstituiraju 1 do 3 R20 skupine; predstavlja [image] gdje:
The IL-17 antagonist for use according to Claim 8, wherein the IL-17 antagonist is a humanized monoclonal antibody or a fully human monoclonal antibody. 
1L-17 antagonist za uporabu u skladu sa zahtjevom 8, naznačen time, da IL-17 antagonist je humanizirano monoklonsko antitijelo ili potpuno ljudsko monoklonsko antitijelo.
A propulsion and steering arrangement according to claim 1, wherein both the upper leading edge (12) and the twisted lower leading edge (13) have a constant twist angle (a, B). 
Raspored pogona i upravljanja prema zahtjevu 1, pri čemu i gornji vodeći rub (12) i torzijski donji vodeći rub (13) imaju konstantni kut torzije (a, B).
packing said stack of gloves (106) in the glove dispensing box by placing an open mouth of the box over said recess (175) and then moving the floor (170) to press the stacked gloves out of said recess and into the open box; and 
- < pakiranje navedenog snopa rukavica (106) u spremnik za doziranje postavljanjem otvorenog otvora spremnika za doziranje putem navedenog udubljenja (175) i pomicanjem poda (170) prema gore da se pritisne naslagane rukavica izvan navedenog udubljenja i u otvoreni otvor kutije dozatora; i
a nucleic acid complementary to a nucleic acid as defined in a); 
nukleinska kiselina komplementarna s nikleinskom kiselinom definiranom pod a),
The method of claim 6 wherein the substance competes with HGF B chain for binding to c-met. 
Postupak prema zahtjevu 6, naznačen time, da se tvar nadmeće s HGF B lancem za vezanje na c-met.
A is R5 is independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, NRCRD, and (NRCRD)carbonyl; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od [image]
Method according to any one of the preceding claims, wherein the fat blend contains HUH triglycerides and HHU triglycerides in a weight ratio of at least 7:1, preferably of at least 7.2:1, wherein H represents a saturated C10-C22 fatty acid residue and U represents an unsaturated C10-C22 fatty acid residue. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što smjesa masti sadrži HUH trigliceride i HHU trigliceride u težinskom omjeru od najmanje 7:1, po mogućnosti od najmanje 7,2:1, gdje H predstavlja ostatak zasićene Cio-C22 masne kiseline, a U predstavlja ostatak nesasićene Cio-C22 masne kiseline.
Use of alpha-ketoglutarate for manufacturing of medicated food product preventing undesired medical conditions related with the presence and/or activity of ureolytic bacteria in vertebrate, including a human being, mammal, bird, amphibian and fish. 
Primjena alfa-ketoglutarata u proizvodnji medicinskog prehrambenog proizvoda, naznačeno time da se timo sprječava neželjene medicinske stanja vezanu uz prisutnost i/ili aktivnost ureolitskih bakterija kod kralješnjaka, uključujući čovjeka, sisavca, pticu, vodozemca ili ribu.
Though endowed with a satisfactory pharmacological profile, the compounds described in the above-mentioned patent applications present kinetics calling for some improvement, in that they are characterised by rapid clearance. 
Premda obdareni sa zadovoljavajućim farmakološkim profilom, spojevi opisani u prethodno spomenutim patentnim prijavama predstavljaju kinetiku koja zahtjeva neka poboljšanja, u tome da su karakterizirani ubrzanim klirensom.
Preparations 4 to 6 describe the preparation of some “sulfide compounds”. 
pripreme 4 do 6 opisuju pripremu nekih Â« sulfidnih spojeva Â«.
The formulation of any of claims 1 to 7, wherein the excipient is a saccharide, a non-reducing sugar and/or polyol. 
Formulacija prema zahtjevu 8, naznačena time što je pomoćna tvar saharid, nereducirajući šećer i/ili poliol.
The process of paragraph 14, wherein said step of converting Compound 10 to Compound 6 comprises reacting Compound 10 with malonic acid in a second solvent. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom u drugom otapalu.
13 shows one embodiment of the ring 1103 that may be coupled to the mouth of the container 1100 . 
Slika 13 prikazuje jedno ostvarenje obruča 1103 koji može biti spojen za vrh posude 1100.
A clinical study was carried out on 36 women with ungual alterations like dystrophy, onycholysis, onychoschizia and ungual brittleness as a result of previous ungual diseases (onychomycosis, psoriasis, bacterial infections) or exogenous causes (chemical agents, trauma, moisture) who volunteered to apply for 28 days a composition obtained by the same method as that indicated in Example 1. 
Klinička studija provedena je na 36 žena s ungualnim promjenama, poput distrofije, oniholize, listanja noktiju i ungualne lomljivosti, kao rezultat prethodne ungualne bolesti (onihomikoze, psorijaze, bakterijskih infekcija) ili egzogenih uzroka (kemijskih agensa, traume, vlage), koje su se dobrovoljno javile da tijekom 28 dana primjenjuju pripravak dobiven istom metodom kakva je prikazana u Primjeru 1.
The extended release tablet formulation of claim 1, wherein at least one of the at least two polymers is a substantially neutral polymer other than pregelatinized starch. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da je najmanje jedan od barem dva polimera u biti neutralan polimer različit od preželatiniziranog škroba.
the exposure to a basic pH is performed at a temperature of 22°C - 28°C or a temperature of 26°C; and/or 
(1i) izloženost lužnatoj pH se izvodi na temperaturi od 22*C do 28*C ili temperaturi od 26C; i/ili
A conjugate produced by the method of claim 17. 
Konjugat proizveden pomoću metode 1z patentnog zahtjeva 17.
The compound of claim 1, wherein R2 is selected from the group consisting of the following moieties: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R" se bira iz skupine koju čine sljedeći ostaci: ove
A method of inducing or enhancing repair, regeneration or enhancement of formation of cartilage, bone or a combination thereof, said method comprising implanting in a subject, a scaffold of claim 1 within a site in need of repair, regeneration or enhancement of formation of cartilage, bone or a combination thereof in said subject. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu je navedena struktura platforme pogodna za nanošenje na kost na tkivo hrskavice u primjeni u postupku induciranja ili pospješenja oporavka, regeneracije ili pospješenja stvaranja hrskavice, kosti ili njihove kombinacije.
A compound of Formula I: 
Formula I gdje:
A human monoclonal anti-interleukin-32 (IL-32) antibody or an IL-32 binding fragment thereof comprising in its heavy (VH) chain and variable light (VL) chain the complementarity determining regions (CDRs) VH-CDR1, VH-CDR2, VH-CDR3 and VL-CDR1, VL-CDR2 and VL-CDR3 selected from 
Humano monoklonsko anti-interleukin-32 (IL-32) protutijelo ili njegov fragment koji veže IL- 32, naznačeno time, da u svom teškom (VH) i varijabilnom lakom lancu (VL) sadržava komplementarnost koja određuje regije (CDR) VH-CDR1, VH-CDR2, VH-CDR3 a VL-CDR1, VL-CDR2 i VL-CDR3 su odabrani od
In a further aspect of the invention, A is COOH. In a further aspect of the invention, suitable compounds of Formula I include, but are not limited to: 4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid; 
Spoj ili sol prema zahtjevu 4, naznačen/a time, da A je COOH. 6. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: 4-(6-hidroksi-3-metilkinolin-2-il)benzoeva kiselina;
Dredging equipment (1) according to claims 4 and 9, characterized in that all the articulations (36,38) provided between pumping line vessel-side part sections (32-24) are cardan couplings. 
Oprema za jaružanje (1) sukladno zahtjevima 4 i 9, naznačena time što su sve artikulacije (36,38) pružene između dijelova strane za liniju za pumpanje (32-24) kardanski zglobovi.
The composition of any one of claims 1 to 9 for use in a method of selectively binding and inhibiting an exogenously administered factor Xa inhibitor in a subject undergoing anticoagulant therapy. 
Pripravak prema zahtjevu 6 naznačen time da je za uporabu kod postupka selektivnog vezanja i inhibicije egzogeno primjenjivanog inhibitora faktora Xa za liječenje prekomjerne antikoagulacije.
The method according to any one of the preceding claims, characterized in that said glycine-lysine-dipeptide is encoded by the nucleic acid ggaaaa, or the nucleic acid ggcaaa, or the nucleic acid gggaaa. 
Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je teški lanac imunoglobulina iz humanog podrazreda IgG1 s mutacijama L234A i L235A.
A smoking article was constructed in accordance with the embodiment of Figure 3. 
Proizvod za pušenje konstruiran je prema realizaciji sa slike 3.
A container according to claim 7, wherein the atmosphere within the sealed container has been modified or controlled. 
Posuda prema Zahtjevu 7, gdje je atmosfera unutar hermetički zatvorene posude izmijenjena ili kontrolirana.
The above condensation or coupling reaction between the 3-aminophthalic acid or a salt thereof and the compound of Formula (X) or a salt thereof may occur in the presence of a catalyst. 
HoN CONH> R! ili njegovom solju s kiselinom, u prisutnosti prvog katalizatora, kako bi se dobilo spoj Formule (LX) ili njegovu sol, solvat, polimorf ili stereoizomer:
Isooctane (2.5 ml) was added to the dark brown solution resulting in crystallisation, the mixture was stirred at room temp for 5 min then isooctane (22.5 ml) was added over 5 min. 
U tamnosmeđu otopinu doda se izooktan (2,5 ml), što dovodi do kristalizacije, smjesu 5 minuta miješa na sobnoj temperaturi, te se 5 minuta dodaje izooktan (22,5 ml).
A developer supply container (1) according to any one of Claims 1 - 5, wherein said drive converting portion (2d, 3b) converts the rotational force such that suction and delivery actions are alternately carried out through said discharge opening (3a) with the reciprocation of said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da se usis i ispuštanje provodi naizmjence kroz navedeni otvor za ispuštanje (3a), obrnuto djelovanju navedenog crpnog dijela (2b).
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
je fenil X, Y je CH2 ili N-oksid, sol, tautomer ili stereoizomer navedenog spoja, ili sol navedenog N-oksida, tautomera ili stereoizomera.
an Ab, or an antigen binding fragment thereof, wherein said Ab binds to human IGF-1R and is selected from the group consisting of: 
Ab, ili njegov fragment vezan na antigen, koji se može vezati za humani IGF-1R odabran od:
Combination according to claim 1, characterized in that the inflammatory disease is a respiratory disease, rheumatism or an auto-immune disease. 
Kombinacija sukladno patentnom zahtjevu 1, naznačena time, da je upalno oboljenje bolest dišnih putova, reumatizam ili autoimuna bolest.
At least one compound as defined in claim 1 for use in the treatment of cytokine-mediated inflammation in an animal, wherein the compound is in an amount sufficient to inhibit cytokine-mediated inflammation and wherein the cytokine-mediated inflammation is associated with increased expression of a pro-inflammatory cytokine and/or with reduced expression of an anti-inflammatory cytokine. 
Barem jedan spoj sa Formulom (I) ili Formulom (II) kako je definiran u zahtjevu 1 naznačen time da je za uporabu kod liječenja bolesti povezane s upalom koja je povezana s razinama ekspresije citokina kod životinje, pri čemu je spoj u količini dovoljnoj /.a liječenje bolesti povezane s upalom pomoću inhibicije pro-upalne ekspresije citokina ili pomoću stimulacije protuupalne ekspresije citokina;
derived from or associated with lung cancer. 
(ii) potječe od ili je povezan s rakom pluća.
The reaction mixture was poured into saturated aqueous sodium sulphite solution (200 ml) and water (200 ml) added. 
Reakcijska smjesa se ulije u zasićenu vodenu otopinu natrij sulfita (200 ml) 1 doda se voda (200 ml).
A lighting module of claim 1, wherein said microchip is configured to operate the switching device such that 880 mA to 910 mA is delivered to the light emitting diode when said thermistor senses between 23°C to 27°C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 680 mA do 910 mA kada navedeni termistor odčita temperaturu u rasponu 23?C€ - 27%C.
R4a is a phenyl group substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, a mono- or di-lower alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group. 
R*"* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;. alkilnom skupinom, Cig alkoksi skupinom, halogen-C;.4 alkoksi skupinom, metilendioksi skupinom, etilenoksi skupinom ili mono- ili di-C,.4 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1.4 alkilnom skupinom ili C;.4 alkoksi skupinom.
The chemical entity of claim 1 or 2, wherein R2 is pyrimidine substituted with one or more members independently selected from group consisting of -CI, -F, -CH3, -CF3, -N(CH3)2, -D, or -CD3. 
Kemijski entitet prema zahtjevu 1 ili 2, gdje R? je pirimidin supstituiran sa jednim ili više članova nezavisno izabranim iz grupe koju čine -CI, -F, -CH., -CF3, -N(CH3),, -D, ili -CD:.
The method of claim 76, wherein the voltage-gated sodium channel is Nav1.8. A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of a compound or salt according to claim 74 or a pharmaceutical composition according to claim 75 . 
Spoj ili sol prema bilo kojem od patentnih zahtjeva od 1 do 41 od 6 do $, amorfni oblik prema patentnom zahtjevu 9, kristalni Oblik B prema patentnom zahtjevu 10 ili farmaceutski pripravak prema patentnom zahtjevu 12 naznačen time što je za upotrebu u postupku liječenja ili smanjenja intenziteta boli kod subjekta s kroničnom boli, crijevnom boli, neuropatskom boli, mišićno-skeletnom boli, akutnom boli, upalnom boli, boli zbog raka, idiopatskom boli, boli nakon kirurške intervencije, visceralnom boli, boli zbog multiple skleroze, Charcot-MarieTooth sindroma, inkontinencije, patološkog kašlja ili srčane aritmije.
The process of claim 1, wherein the process further comprises the steps of: draining a dirty liquid stream from the light stream; and 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu process dalje obuhvaća korake: dreniranja toka nečiste tekućine iz laganog toka, i
The pharmaceutical composition of claim 18, further comprising a second antibody or antigen-binding fragment specific for a second epitope. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što dodatno sadrži drugo protutijelo ili antigenski vežući fragment specifičan za drugi epitop.
The process according to Claim 7, wherein the post-translational modification group is labeled simultaneously with cleavage. 
Postupak prema zahtjevu 1, naznačen time da je post-translacijska modifikacijska skupina označena istovremeno uz cijepanje.
The arrangement for preventing egress of a gas from a first opening of a vessel as claimed in claim 2 wherein the surface of the first opening between the open passage and the vessel comprises a Coanda surface. 
Sustav za sprječavanje izbacivanja plina iz prvog otvora spremnika prema bilo kojem od zahtjeva 3 do 6, pri čemu je otvoreni prolaz (48) u fluidnoj komunikaciji s plenum komorom (44).
wherein R1 represents an optionally substituted C1-6 alkyl group; one of R2 and R3 represents a hydrogen atom; and the other of R2 and R3 represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group. 
R jedan od R2 i R3 predstavlja atom vodika, a drugi od R, i Rz predstavlja atom vodika, po izboru supstituiranu amino skupinu, po izboru supstituiranu acilamino skupinu, po izboru supstituiranu karbamoilnu skupinu ili po izboru supstituiranu arilnu skupinu.
The process according to any one of claims 1-6 further comprising the chlorination of (S)-2-acetyloxypropionic acid to (S)-2-acetyloxypropionyl chloride in the presence of thionyl chloride (SOCl2) in a continuous mode. 
Postupak prema bilo kojem od zahtjeva 1-6 naznačen time što nadalje sadrži kloriranje (S)-2-acetiloksipropionske kiseline u (S)-2-acetiloksipropionil klorid u prisutnosti tionilovog klorida (SOCL) u kontinuiranom postupku.
Composition of 100 mg dry powder: 
Sastav 100 mg suhog praha:
Compounds of general formula VI according to claim 9, in form of a racemic mixture or as enantiomerically pure isomer. 
Spojevi opće formule VI prema zahtjevu 9, [image] u obliku racemske smjese ili kao enantiomerno čisti izomer.